Science & Health
People Are Skipping Sleep Aids In Favor of Marijuana, Study Reports
The scientific community is still unclear on whether or not marijuana can actually help treat sleep disturbances such as insomnia. A new study, however, found that fewer people purchase over-the-counter (OTC) sleep medications when they have legal access to cannabis.
“Our results show that the market share growth for sleep aids shrank with the entry of recreational cannabis dispensaries by more than 200% relative to the mean market share growth in our sample, and the strength of the association increased with each subsequent dispensary,” the paper, published in the December edition of Complementary Therapies in Medicine, concludes. “In particular, cannabis appears to compete favorably with OTC sleep aids, especially those containing diphenhydramine and doxylamine, which constitute 87.4% of the market for OTC sleep aids.”
“Recreational cannabis dispensaries greatly increase the number of individuals able to legally treat sleep disorders using cannabis, particularly those with mild to moderate sleep disorders.”
Researchers at the University of New Mexico and California State Polytechnic University used retail scanner data collected by the Nielsen Company to help them understand how access to recreational marijuana affected the sales of OTC sleep medications purchased at local stores in Colorado.
In their analysis, they studied the market shares of overall sleep aids—including supplements such as melatonin and pharmaceuticals such as diphenhydramine—at 587 stores. They also used monthly data from the Colorado Department of Revenue to compare the number of recreational dispensaries in each county as well as local cannabis retail sales figures.
“The negative association between cannabis access and sleep aid sales suggests a consumer preference for cannabis.”
It became legal for Colorado residents to purchase cannabis for adult use on January 1, 2014, and the study period covered December 2013 through December 2014.
According to the results, the market share for sleep aids was neither rising nor declining prior to a dispensary opening in the same county. After one did, however, the market share declined with each month of its existence. A regression model showed that sleep aid market share growth decreased by 236 percent after a dispensary entered the market, and this negative association increased as the number of dispensaries grew.
“The magnitude of the market share decline increases as more dispensaries enter a county and with higher county-level cannabis sales.”
“For the first time, we show a statistically significant negative association between recreational access to cannabis and OTC sleep aid sales, suggesting that at least some recreational purchasers are using cannabis for therapeutic rather than recreational purposes,” the study’s authors write.
“Additionally, despite a lack of direct clinical evidence on the effectiveness of self-managed cannabis as a sleep aid, our results indicate that enough individuals are switching from OTC sleep aids to recreational cannabis that we can identify a statistically significant reduction in the market share growth of OTC sleep aids in conjunction with access to recreational cannabis using a statistically conservative county-month-level treatment variable and a quasi-experimental research design,” the paper concluded.
“Our results are consistent with evidence that legal access to medical cannabis is associated with reductions in Scheduled II-V prescription medications (e.g., opioids and sedatives), many of which may be used in part as sleep aids,” the authors wrote.
“These findings support survey evidence that many individuals use cannabis to treat insomnia, although sleep disturbances are not a specific qualifying condition under any U.S. state-level medical cannabis law.”
Study author Sarah Stith, an applied microeconomist at the University of New Mexico, explained in a statement: “From a public health perspective, the possible widespread use of cannabis for less severe medical conditions both highlights its therapeutic potential and raises concerns regarding the risk-benefit tradeoffs of substituting a substance associated with abuse and dependence for relatively ineffective OTC medications with typically low levels of abuse potential.”
“From an economic or business perspective, regardless of underlying mechanism, our documentation of changing purchase behaviors has implications for multimillion-dollar US markets with OTC sleep aids likely just one example,” she said. “It is important for the medical community to recognize that the lack of medical guidance does not necessarily lead to a lack of medical use. Dispensaries and online forums are stepping up to fill the information vacuum as individuals are forced to take treatment into their own hands, with statistically evident effects on treatment choices.”
A ‘Significant’ Number Of Patients Stopped Taking Benzodiazepines After Starting Medical Marijuana
Photo by Wesley Gibbs on UnsplashÂ
Science & Health
Dogs Are Being Exposed To Marijuana Through Human Poop And Pet Owners Should Beware, Study Finds
A word of caution to dog owners: apparently some canines are getting intoxicated off marijuana by eating the feces of people who’ve consumed cannabis, according to a new study.
Dogs are natural scavengers, and so the instinct to eat poop—while gross—is just a fact of life. But a team of Australian researchers found that, in some cases, that instinct can become dangerous, warranting the attention of puppy parents.
The study, published in the Australian Veterinary Journal, looked at 15 cases of confirmed THC toxicosis in dogs who were suspected of, or observed to have, ingested human feces in Melbourne from 2011-2020.
The dogs presented symptoms of incoordination, dilated pupils, urinary incontinence and stupor. Urine tests from eight of the dogs showed THC metabolites in their system.
However, study author Clara Lauinger told Marijuana Moment that this shouldn’t necessarily be taken to mean that any level of THC is toxic in dogs.
“The animals in my study had ingested an unknown quantity of feces that contained an unknown concentration of THC and so one would assume this concentration would be at a level that clearly caused toxicity,” she wrote in an email. “However this does not mean that all THC ingestions can lead to toxicity.”
In fact, there are other studies where animals were administered a controlled dosage of THC and “not a single one of them displayed any adverse effects that we might see with toxicity,” she said.
“There are so so many anecdotal reports of the huge benefits that THC administration has on animals, albeit reports are from owners perception rather than peer reviewed research, but this does not mean the industry should disparage THC as a therapeutic agent,” Lauinger said.
Most of the dogs in her new study apparently ate the poop at local parks, while others ingested it at the beach, camp sites and walking trails.
“All dogs survived to discharge. Ingestion of human feces containing THC may lead to marijuana toxicosis in dogs,” the study states. “Veterinary staff and owners should be attentive in regard to using appropriate hygiene measures when managing these dogs.”
The authors said that there are a number of reasons that a dog might eat poop—or, put scientifically, engage in coprophagy. But they floated one possibility for the marijuana-specific feces-eating trend: “It is possible that the presence of marijuana in feces increases its attractiveness for ingestion by altering its scent, texture and/or taste.”
Also, while this study is limited to data on about two dozen dogs in one city of Australia, the authors also said that the habit “might be more common than what owners report,” pointing to Google search results from people reporting a dog ate feces and exhibited signs of lethargy.
The idea of dogs getting high off THC-containing human waste might seem like a stretch on its own, but the study also explains that canines have more cannabinoid receptors than humans, “making dogs more sensitive to the effects of THC.”
“In conclusion, this case series suggests that ingestion of feces produced by a human marijuana user may lead to signs of marijuana toxicosis,” the researchers said. “Clinical signs of toxicosis were similar to those previously reported for dogs with conrmed marijuana toxicosis though gastrointestinal signs were not the most common feature despite coprophagy.”
“Veterinary staff and owners should be mindful of this exposure source to ensure appropriate hygiene measures are taken when managing these dogs,” the study says.
Lauinger said that there “needs to be an industrywide understanding of the fact that there are so many different strains of cannabis and each of these strains has different cannabinoid profiles that have possible potential for beneficial therapeutic effects.”
“These strains could be researched with a focus on what ones are suitable for animals and at what dose rather than blanketing all strains as being toxic,” she said. “I hope the public can be patient and also get behind us researching the dosing more.”
While there are clear concerns about dogs ingesting excess levels of THC, studies have found promising results when it comes to the therapeutic potential of other cannabinoids like CBD for pets.
For example, dogs with epilepsy experience considerably fewer seizures when treated with CBD oil, a study published in the journal Pet Behaviour Science in 2019 found.
The prior year, a separate study determined that CBD can alleviate the symptoms of osteoarthritis in dogs.
The Food and Drug Administration (FDA), for its part, has repeatedly warned pet owners about using CBD to treat firework-related anxiety in pets around the July 4 holiday.
“You should be aware that FDA has NOT evaluated these products and can’t say whether they are safe or effective, how they are manufactured, or whether they contain CBD,” the agency said this year.
Photo courtesy of Pexels.
Science & Health
Psychedelics Use Associated With 55 Percent Decrease In Daily Opioid Consumption, Study Finds
The use of psychedelics like LSD, psilocybin, mescaline and DMT is associated with a significant decrease in illicit opioid consumption, according to a new study.
Researchers looked at data from “three harmonized prospective cohorts of community-recruited” people with substance misuse disorders. A total of 3,813 individuals were involved, including 1,093 who reported illicit opioid consumption and 229 who said they’d used psychedelics in the past six months.
“Recent psychedelic use was associated with 55% reduced odds of daily opioid use,” the Vancouver-based study, published last week in the Journal of International Drug Policy, found.
While there have been numerous studies connecting legal marijuana access to reduced opioid use and fewer overdose deaths, this is “the first longitudinal study to link psychedelic use with lower daily opioid use,” the paper says.
“Over study follow-up after adjusting for a range of potential confounders, psychedelic use remained independently associated with a significantly reduced odds of subsequent daily opioid use,” the study states. “While confirmation in other settings is required, these findings align with growing evidence that psychedelic use may be associated with detectable reductions in subsequent substance use including illicit opioid use.”
While there’s not a clear explanation for the trend—and the researchers urged additional studies—psychedelics like psilocybin and MDMA have been touted as potentially powerful tools in mental health treatment, effectively treating conditions like severe depression, post-traumatic stress disorder and addiction.
“These findings align with growing evidence demonstrating that psychedelic use may be associated with detectable reductions in subsequent opioid use, and warrant further research on psychedelics for opioid and other substance use disorders,” the study’s lead author, Elena Argento of the University of British Columbia, told Marijuana Moment.
“This study found naturalistic psychedelic use to be independently associated with a significantly reduced odds of subsequent daily illicit opioid use among a community-based sample of [people who use drugs],” the study concluded. “More research with controlled trials and longer-term follow-up is required to elucidate the therapeutic potential of psychedelics to augment existing interventions for substance use disorders, including among more diverse populations. Additional qualitative studies would also provide opportunities to improve understanding of the possible psycho-social mechanisms underpinning psychedelic experiences.”
Another recent study found that when people use cannabis together with psychedelics, it was “associated with higher scores of mystical-type experience, ego-dissolution and visual alterations.”
With respect to marijuana alone, a study published earlier this year found that cannabis use is associated with significant reductions in dependence on opioids and other prescription drugs, as well as an increase in quality of life
Another study released last year determined that states with active medical marijuana laws saw certain opioid prescription rates drop nearly 20 percent compared to prohibition states.
Using Marijuana With Psychedelics Intensifies The Mystical Experience, Study Finds
Photo elements courtesy of carlosemmaskype and Apollo.
Science & Health
Marijuana Legalization In Canada Did Not Result In Increased Traffic Injuries, Study Finds
Canada’s move to legalize marijuana did not result in increased traffic injuries, a new study has found.
In a paper published in the journal Drug and Alcohol Dependence, researchers said they sought to investigate claims that establishing the cannabis legalization law, which took effect in October 2018, would make roads less safe, as prohibitionists frequently argue.
But after analyzing Ontario and Alberta emergency department data from April 2015 to December 2019, however, they couldn’t find any evidence to support that hypothesis.
“Implementation of the Cannabis Act was not associated with evidence of significant post-legalization changes in traffic-injury [emergency department] visits in Ontario or Alberta among all drivers or youth drivers, in particular,” the study states.
“Legalization not associated with changes in traffic injuries in all drivers or youth drivers.”
That’s despite the fact that “worldwide momentum toward legalization of recreational cannabis use has raised a common concern that such policies might increase cannabis-impaired driving and consequent traffic-related harms, especially among youth.”
The study’s lead author, Russ Callaghan, said in a press release that his team’s results “show no evidence that legalization was associated with significant changes in emergency department traffic-injury presentations.”
The researcher admitted that the outcome of the study is “somewhat surprising,” adding that he “predicted that legalization would increase cannabis use and cannabis-impaired driving in the population, and that this pattern would lead to increases in traffic-injury presentations to emergency departments.”
“It is possible that our results may be due to the deterrent effects of stricter federal legislation, such as Bill C-46, coming into force shortly after cannabis legalization,” he said, referring to a separate impaired driving bill. “These new traffic-safety laws imposed more severe penalties for impaired driving due to cannabis, alcohol, and combined cannabis and alcohol use.”
While Callaghan said he wasn’t expecting the results that his team ended up with, there is a body of existing research that’s also challenged the idea that legalization leads to increased traffic risks.
A U.S. congressional research body said in a 2019 report that concerns expressed by lawmakers that cannabis legalization will make the roads more dangerous might not be totally founded. In fact, the experts tasked by the House and Senate with looking into the issue found that evidence about cannabis’s ability to impair driving is currently inconclusive.
Other researchers have found on several occasions that traffic fatalities do not increase after a state legalizes marijuana.
A study published in the Journal of the American Medical Association late last year found that small doses of CBD appear to have no significant impact on driving, whereas comparable doses of THC were associated with short-term impairment “modest in magnitude and similar to that seen in drivers with a 0.05%” blood alcohol concentration.
In any case, House-approved report language related to funding for the Departments of Transportation, and Housing and Urban Development addresses drug-impaired driving from substances such as marijuana and urges the National Highway Traffic Safety Administration to take steps to address the issue.
DEA Boosts Psilocybin, MDMA And DMT Production Levels Again In Final Quotas For 2021
